Stock Track | Absci Shares Plunge 16.77% After-Hours on Q3 Revenue Miss and Wider Losses

Stock Track11-13

Shares of Absci Corporation (NASDAQ: ABSI) tumbled 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results, which fell short of analysts' expectations.

The biotech company, which specializes in AI-powered drug discovery, reported revenue of $378,000 for the quarter ended September 30, 2025, significantly missing the analyst consensus estimate of $1.52 million. This represents a steep 77.78% decrease from the $1.7 million reported in the same period last year. The company's net loss widened to $28.7 million, or $0.20 per share, compared to $27.4 million, or $0.24 per share, in the prior year period.

Despite the revenue miss, Absci's loss per share of $0.20 narrowly beat the analyst estimate of $0.21. However, this slight beat was not enough to offset investor concerns about the company's declining revenue and expanding losses. The company's operating expenses increased to $30.5 million, up from $27.3 million in the same quarter last year, primarily due to higher research and development costs associated with the advancement of internal programs. Absci ended the quarter with $152.5 million in cash, cash equivalents, and marketable securities, providing a runway for continued operations and research initiatives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119470257?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119470257","market":"us","top_or_hot":-1,"title":"Stock Track | Absci Shares Plunge 16.77% After-Hours on Q3 Revenue Miss and Wider Losses","media":"Stock Track","content":"<p>Shares of Absci Corporation (NASDAQ: ABSI) tumbled 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results, which fell short of analysts' expectations.</p>\n\n<p>The biotech company, which specializes in AI-powered drug discovery, reported revenue of $378,000 for the quarter ended September 30, 2025, significantly missing the analyst consensus estimate of $1.52 million. This represents a steep 77.78% decrease from the $1.7 million reported in the same period last year. The company's net loss widened to $28.7 million, or $0.20 per share, compared to $27.4 million, or $0.24 per share, in the prior year period.</p>\n\n<p>Despite the revenue miss, Absci's loss per share of $0.20 narrowly beat the analyst estimate of $0.21. However, this slight beat was not enough to offset investor concerns about the company's declining revenue and expanding losses. The company's operating expenses increased to $30.5 million, up from $27.3 million in the same quarter last year, primarily due to higher research and development costs associated with the advancement of internal programs. Absci ended the quarter with $152.5 million in cash, cash equivalents, and marketable securities, providing a runway for continued operations and research initiatives.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Absci Shares Plunge 16.77% After-Hours on Q3 Revenue Miss and Wider Losses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Absci Shares Plunge 16.77% After-Hours on Q3 Revenue Miss and Wider Losses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 05:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Absci Corporation (NASDAQ: ABSI) tumbled 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results, which fell short of analysts' expectations.</p>\n\n<p>The biotech company, which specializes in AI-powered drug discovery, reported revenue of $378,000 for the quarter ended September 30, 2025, significantly missing the analyst consensus estimate of $1.52 million. This represents a steep 77.78% decrease from the $1.7 million reported in the same period last year. The company's net loss widened to $28.7 million, or $0.20 per share, compared to $27.4 million, or $0.24 per share, in the prior year period.</p>\n\n<p>Despite the revenue miss, Absci's loss per share of $0.20 narrowly beat the analyst estimate of $0.21. However, this slight beat was not enough to offset investor concerns about the company's declining revenue and expanding losses. The company's operating expenses increased to $30.5 million, up from $27.3 million in the same quarter last year, primarily due to higher research and development costs associated with the advancement of internal programs. Absci ended the quarter with $152.5 million in cash, cash equivalents, and marketable securities, providing a runway for continued operations and research initiatives.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABSI","symbol_name":"Absci Corporation.","start_time":0,"source_url":"","article_id":"1119470257","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119470257","pubTimestamp":1762983191,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Absci Corporation (NASDAQ: ABSI) tumbled 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results, which fell short of analysts'...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABSI":"Absci Corporation."},"translate_title":"个股追踪|Absci股价盘后暴跌16.77%，因Q3营收未达预期且亏损扩大","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":1},"content_text":"Shares of Absci Corporation (NASDAQ: ABSI) tumbled 16.77% in after-hours trading on Wednesday following the release of its third-quarter 2025 financial results, which fell short of analysts' expectations.\nThe biotech company, which specializes in AI-powered drug discovery, reported revenue of $378,000 for the quarter ended September 30, 2025, significantly missing the analyst consensus estimate of $1.52 million. This represents a steep 77.78% decrease from the $1.7 million reported in the same period last year. The company's net loss widened to $28.7 million, or $0.20 per share, compared to $27.4 million, or $0.24 per share, in the prior year period.\nDespite the revenue miss, Absci's loss per share of $0.20 narrowly beat the analyst estimate of $0.21. However, this slight beat was not enough to offset investor concerns about the company's declining revenue and expanding losses. The company's operating expenses increased to $30.5 million, up from $27.3 million in the same quarter last year, primarily due to higher research and development costs associated with the advancement of internal programs. Absci ended the quarter with $152.5 million in cash, cash equivalents, and marketable securities, providing a runway for continued operations and research initiatives.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119470257","isCrawlerRequest":true}